Familial Platelet Disorder, Hematopoietic
Conditions
Brief summary
To learn about the safety and effects of low-dose sirolimus in participants with RUNX1-FPD.
Detailed description
Primary Objective: • Evaluate the safety and tolerability of low-dose sirolimus in participants with RUNX1 familial platelet disorder (RUNX1-FPD) Secondary Objectives: * Evaluate increases in platelet counts during and after treatment with low-dose sirolimus * Evaluate changes in somatic mutation variant allele frequency (VAF) * Monitor the rate of somatic mutation acquisition (ie, mutation burden) * Assess change in platelet aggregation score * Measure the change from baseline in bleeding score (ISTH-BAT) * Evaluate change in mTORC1 downstream signaling (pS6/EBP) Exploratory Objectives: * Measure rescue of elevated cytokine profiles * Evaluate reversal of myeloid skewing using flow cytometry * Determine changes in bone marrow (eg, megakaryocytic atypia and cellularity) * Assess changes in patient-reported outcomes measures (eg, EORTC and PRO-CTCAE) * Describe the pharmacokinetics of sirolimus in patients with RUNX1-FPD * Determine the correlation between sirolimus trough levels and each endpoint
Interventions
DRUGSirolimus
Given by PO
Sponsors
M.D. Anderson Cancer Center
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Participants has provided signed, informed consent before initiation of any study specific procedures * Aged ≥18 years at the time of signing the informed consent * Confirmed P/LP germline RUNX1 variant per ClinGen Myeloid Malignancy Variant Curation Expert Panel (MM-VCEP) RUNX1-specific variant curation rules80 * Participants must be willing to provide bone marrow sample at time of screening and at the end of treatment with sirolimus * Platelet count of ≥50,000/µL * Adequate renal function: estimated glomerular filtration rate based on Modification of Diet in Renal Disease (MDRD) calculation, \>30 mL/min/1.73m2 * Adequate hepatic function: aspartate aminotransferase (AST) and alanine aminotransferase (ALT) \<3 × upper limit of normal (ULN) and total bilirubin \<1.5 × ULN * Adequate cardiac function: left ventricular ejection fraction \>50%
Exclusion criteria
* Known allergy to sirolimus * History of lymphoma or other hematologic malignancies * Uncontrolled bleeding * Any prior diagnosis of myelodysplastic syndrome or other hematologic malignancy using International Working Group criteria * Prior treatment with sirolimus or a rapalog, mTOR inhibitor, or B-cell-depleting therapy within 28 days before study day 1 * Treatment with strong inhibitors of cytochrome P450 3A4 (CYP3A4; eg, ketoconazole, voriconazole, itraconazole, erythromycin, telithromycin, and clarithromycin), strong inducers of CYP3A4 (eg, rifampin and rifabutin), other drugs that could increase sirolimus blood concentrations (eg, bromocriptine, cimetidine, cisapride, clotrimazole, danazol, diltiazem, fluconazole, letermovir, protease inhibitors \[eg, ritonavir, indinavir, boceprevir, and telaprevir\], metoclopramide, nicardipine, troleandomycin, and verapamil), other drugs that could decrease sirolimus blood concentrations (eg, carbamazepine, phenobarbital, phenytoin, rifapentine, St. John's Wort \[Hypericum perforatum\]), or drugs with blood concentrations that could increase (eg, verapamil) within 7 days before study day 1 * Use of cannabidiol, which can increase blood levels of sirolimus, within 7 days before study day 1 * Myocardial infarction within 6 months before study day 1, congestive heart failure (New York Heart Association \> class II) * Total cholesterol \>300 mg/dL or triglyceride \>400 mg/dL * Arterial thrombosis (eg, stroke or transient ischemic attack) within 6 months before study day 1 * Infection requiring intravenous anti-infective treatment within 1 week of study day 1 * Live vaccines (eg, measles, mumps, rubella, oral polio, BCG, yellow fever, varicella, and TY21a typhoid) within 28 days before study day 1 * Known diagnosis of chronic viral infection (eg, hepatitis B or C or HIV, and Epstein-Barr) or tuberculosis * Women who are pregnant, may become pregnant, or who are breastfeeding
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Safety and adverse events (AEs) | Through study completion; an average of 1 year | Incidence of Adverse Events, Graded According to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version (v) 5.0 |
Countries
United States
Contacts
CONTACTCourtney DiNardo, MD
PRINCIPAL_INVESTIGATORCourtney DiNardo, MD
M.D. Anderson Cancer Center
Outcome results
None listed